Smith & Nephew PLC (LSE:SN.) - Share price

Stock Report

Smith & Nephew PLC SN.

Last Price

Day Change

As of 28/06/2022
18:10:12 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,165.00p
Day Range1,155.50 - 1,173.00
Mkt Cap10.16Bil
52-Wk Range1,108.00 - 1,601.50
Yield %2.48

Share Price

Total Returns 27/06/2022

 Chg (%)  
More ...
Smith & Nephew PLC-10.11 
FTSE 100 TR GBP-4.09
More ...
Income Statement
Operating Profit1,014.00491.00721.00
Net Profit600.00448.00524.00
Reported EPS0.680.510.60
Balance Sheet
Current Assets3,219.004,664.004,424.00
Non Current Assets6,080.006,348.006,496.00
Total Assets9,299.0011,012.0010,920.00
Current Liabilities1,564.001,688.002,131.00
Total Liabilities4,158.005,733.005,352.00
Total Equity5,141.005,279.005,568.00
Cash Flow
Operating Cash Flow1,318.00913.00974.00
Net Change in Cash-76.001,493.00-459.00

Regulatory News

DateAuthor Headline
16/08/2017Emma Simon Investor Views: "I’ve Doubled My Money in Utility Shares"
Retired investor Gordon Pope began buying shares in the 1980s and hopes his portfolio will supplement his pension income
24/07/2017Emma Wall 5 Undervalued UK Stock Picks
The Morningstar Fair Value Estimate tells investors what the long-term, intrinsic value of a stock is. So which UK stocks are trading at less than their fair value?
02/02/2017Karen Kwok UK Pharma Stocks Fall as Trump Repeals Obamacare
UK healthcare companies have lost value after Trump signed an executive order last month to repeal the Affordable Care Act, also known as Obamacare

Company Profile

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.


Medical Devices


FTSE 100 , FTSE 350 , FTSE All Share , FTSE Eurotop 300 , FTSE techMARK Focus

Next Event 28/07/2022

Half-Yearly Results
More ...
PER (E)27.39
Div Yld (E)2.24
PEG (E)1.24
Op Mrgn0.14
EPS Grwth-0.06
More ...
Record Date01/10/2101/04/22
More ...
Non-Executive DirectorMr. Marc E. Owen
Non-Executive DirectorMr. Erik Engstrom
Non-Executive Director, Senior Independent Non-Executive DirectorMr. Robin A D Freestone
Non-Executive Director, ChairmanMr. Roberto Quarta
Non-Executive DirectorMr. Charles Richard Medlock
Non-Executive DirectorMs. Angie Risley
Executive Director, Chief Financial OfficerMs. Anne-Francoise Nesmes
Non-Executive DirectorMr. Robert J. White
Executive Director, Chief Executive OfficerMr. Roland Daniel Diggelmann
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.